Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib

Abstract Background Tropomyosin receptor kinase (TRK) fusion proteins resulting from neurotrophic tyrosine receptor kinase (NTRK) gene fusions are rare primary oncogenic drivers in a wide array of tumors. Larotrectinib is a first-in-class, highly selective, central nervous system-active TRK inhibito...

Volledige beschrijving

Bibliografische gegevens

Hoofdauteurs:	James C. H. Yang, Marcia S. Brose, Gilberto Castro, Edward S. Kim, Ulrik N. Lassen, Serge Leyvraz, Alberto Pappo, Fernando López-Ríos, John A. Reeves, Marc Fellous, Frédérique Penault-Llorca, Erin R. Rudzinski, Ghazaleh Tabatabai, Gilles Vassal, Alexander Drilon, Jonathan Trent
Formaat:	Artigo
Taal:	Inglês
Gepubliceerd in:	BMC 2022-06-01
Reeks:	BMC Cancer
Onderwerpen:	Larotrectinib NTRK gene fusions TRK fusion Non-interventional study
Online toegang:	https://doi.org/10.1186/s12885-022-09687-x
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!